11/22
08:46 am
abeo
Critical Care Therapeutics Industry Opportunities by Drug Class and Application with Regional Market Breakdowns, 2025-2030: Integration of AI and ML in Drug Development Offers Untapped Opportunities [Yahoo! Finance]
Medium
Report
Critical Care Therapeutics Industry Opportunities by Drug Class and Application with Regional Market Breakdowns, 2025-2030: Integration of AI and ML in Drug Development Offers Untapped Opportunities [Yahoo! Finance]
11/20
03:11 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
02:22 am
abeo
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/14
07:57 am
abeo
Abeona Therapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Abeona Therapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
11/14
07:39 am
abeo
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Medium
Report
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
11/14
07:30 am
abeo
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Medium
Report
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
11/13
12:08 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/12
01:56 pm
abeo
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment [Seeking Alpha]
Low
Report
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment [Seeking Alpha]
11/12
07:30 am
abeo
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Medium
Report
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
11/7
02:07 pm
abeo
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio [Yahoo! Finance]
Low
Report
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio [Yahoo! Finance]
11/4
07:30 am
abeo
Abeona Therapeutics® Announces Participation in November Investor Conferences
Medium
Report
Abeona Therapeutics® Announces Participation in November Investor Conferences
11/1
07:30 am
abeo
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/31
08:35 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
10/29
12:22 pm
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
10/29
07:30 am
abeo
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Low
Report
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
10/3
08:12 am
abeo
Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy [Seeking Alpha]
Low
Report
Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy [Seeking Alpha]
10/1
07:30 am
abeo
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/20
11:27 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
Medium
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
9/10
02:02 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
9/3
07:30 am
abeo
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Medium
Report
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
9/2
11:01 pm
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
9/2
07:30 am
abeo
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)